Vertex Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary

Vertex Pharmaceuticals Incorporated

03/08/2026 22:01

Vertex Pharmaceuticals Inc VRTX.OQ reported quarterly adjusted earnings of $4.73​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $4.52.  The mean expectation of twenty seven analysts for the quarter was for earnings of $4.73 per share. Wall Street expected results to range from $4.26  to $5.17 per share.
Revenue rose 12.5% to $3.33 billion from a year ago; analysts expected $3.23 billion. 
Vertex Pharmaceuticals Inc's reported EPS for the quarter was $4.31​.
The company reported quarterly net income of $1.1 billion.
Vertex Pharmaceuticals Inc shares had fallen by 4.0% this quarter and gained 5.2% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 0.4% in the last three months.​ 
In the last 30 days, five analysts negatively revised earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 25 "strong buy" or "buy," 5 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy" 
Wall Street's median 12-month price target for Vertex Pharmaceuticals Inc is $570.00, about 16.3% above its last closing price of $477.10
This summary was machine generated from LSEG data August 3 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
4.73
4.73
Met
Mar. 31 2026 
4.31
4.47
Beat
Dec. 31 2025 
5.07
5.03
Missed
Sep. 30 2025 
4.56
4.80
Beat